Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
12/9/25 Galapagos (GLPG) GLPG5101 for Mantle Cell Lymphoma - NHL Subscribers Only Subscribers Only Subscribers Only
12/8/25 Geron (GERN) Rytelo for Myelodysplastic Syndrome (MDS) Subscribers Only Subscribers Only Subscribers Only
12/8/25 AROG Crenolanib for Acute Myelogenous Leukemia (AML) Subscribers Only Subscribers Only Subscribers Only
12/8/25 MaaT Pharma Xervyteg for Graft vs. Host Disease (GVHD) - Treatment Subscribers Only Subscribers Only Subscribers Only
12/7/25 Ascentage Pharma (6855) olverembatinib for Chronic Myelogenous Leukemia (CML) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/26/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/30/2025 Subscribers Only Subscribers Only Trial Announcement - Patient Enrollment Completed
01/01/2026 - 06/30/2025 Subscribers Only Subscribers Only Trial Announcement - Initiation